NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $0.97 -0.06 (-6.04%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$0.97 +0.00 (+0.33%) As of 07:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lucid Diagnostics Stock (NASDAQ:LUCD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$0.96▼$1.0250-Day Range$0.95▼$1.1152-Week Range$0.90▼$1.63Volume2.99 million shsAverage Volume1.65 million shsMarket Capitalization$196.53 millionP/E RatioN/ADividend YieldN/APrice Target$4.19Consensus RatingModerate Buy Company Overview Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients. Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States. The company’s test is billed under existing procedural codes, and Lucid engages with payers to secure coverage and reimbursement. In addition to its core oral cancer test, the company is developing complementary assays and workflow enhancements aimed at broadening its diagnostic portfolio and supporting earlier intervention in head and neck malignancies. Headquartered in the Pacific Northwest, Lucid Diagnostics began trading on the NASDAQ under the ticker LUCD in mid-2021 following a strategic reorganization and capital raise. The senior management team comprises professionals with backgrounds in in-vitro diagnostics, clinical laboratory operations and life-science commercialization. Looking ahead, Lucid is focused on expanding its sales footprint, advancing payer relationships and exploring international distribution agreements to extend access to its non-invasive oral cancer detection platform.AI Generated. May Contain Errors. Read More Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreLUCD MarketRank™: Lucid Diagnostics scored higher than 64% of companies evaluated by MarketBeat, and ranked 246th out of 844 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingLucid Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialLucid Diagnostics has a consensus price target of $4.19, representing about 332.7% upside from its current price of $0.97.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 4 research reports in the past 90 days.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.23) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lucid Diagnostics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.93% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 21.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $245,000.00 in company stock, which represents 0.1247% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $245,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders6.90% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LUCD Stock News HeadlinesLucid Diagnostics (NASDAQ:LUCD) Downgraded to "Sell" Rating by Wall Street ZenJuly 4, 2026 | americanbankingnews.comLucid Diagnostics: Positioned For A Medicare-Driven InflectionJuly 3, 2026 | seekingalpha.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 9 at 1:00 AM | Banyan Hill Publishing (Ad)Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 2, 2026 | americanbankingnews.comLucid Diagnostics Shareholders Approve Stock Authorization IncreaseJune 24, 2026 | tipranks.comLucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks TranscriptJune 24, 2026 | seekingalpha.comLucid Diagnostics’ Earnings Call: Momentum Amid Cash StrainJune 12, 2026 | theglobeandmail.comCanaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)May 16, 2026 | theglobeandmail.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $1.09 at the beginning of 2026. Since then, LUCD stock has decreased by 11.2% and is now trading at $0.9678. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) posted its earnings results on Wednesday, May, 13th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The company earned $1.26 million during the quarter, compared to analyst estimates of $1.38 million. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an initial public offering on Tuesday, October 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU). Company Calendar Last Earnings5/13/2026Today7/09/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 LUCD's financial health is in the Yellow zone, according to TradeSmith. LUCD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees70Year Founded1991Price Target and Rating Average Price Target for Lucid Diagnostics$4.19 High Price Target$9.25 Low Price Target$2.00 Potential Upside/Downside+332.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.01 million Net Margins-876.72% Pretax Margin-876.72% Return on EquityN/A Return on Assets-116.26% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.05 Sales & Book Value Annual Sales$4.71 million Price / Sales41.73 Cash FlowN/A Price / Cash FlowN/A Book Value($0.31) per share Price / Book-3.12Miscellaneous Outstanding Shares203,070,000Free Float189,055,000Market Cap$196.53 million OptionableNo Data Beta1.07 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:LUCD) was last updated on 7/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
